Patent US5576345A successfully refreshed from Google Patents.
US5576345A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and means for inhibiting posterior capsule opacification
Assignee: Pfizer Health AB
•
Filing: 1994-04-26
•
Granted: 1996-11-19
•
Expires: 2014-04-26
Abstract
Abstract The present invention is directed to the use of taxol or a pharmaceutically and ophthalmologically acceptable derivative thereof for the prevention of secondary cataracts after extracapsular extraction with or without intraocular lens implantation.
Inventors
- 👤 Per Månsson
- 👤 Wenche Rolfsen
- 👤 Kerstin Wickstr om
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 01:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61P; A61P27/00; A61P27/02; A61P27/12; A61K9/00; A61K9/0012; A61K9/0048
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
30 words
A method for preventing secondary cataract after extracapsular cataract extraction, comprising administering taxol or a pharmaceutically active and ophthalmologically acceptable derivative thereof to the intraocular area after extracapsular cataract extraction.
Claim 2
Independent Claim
30 words
A method for preventing secondary cataract after extracapsular cataract extraction, comprising administering taxol or a pharmaceutically active and ophthalmologically acceptable derivative thereof to the intraocular area after extracapsular cataract extraction.
Claim 3
Dependent Claim
24 words
A method as defined by claim 1, wherein an intraocular lens is implanted in the intraocular area before, simultaneous with or after said administration.
Claim 4
Dependent Claim
24 words
A method as defined by claim 1, wherein no intraocular lens is implanted in the intraocular area before, simultaneous with or after said administration.
Claim 5
Dependent Claim
24 words
A method as defined by claim 1, wherein the taxol or the derivative thereof is administered in an amount of up to 25 μg.
Claim 6
Dependent Claim
26 words
A method as defined by claim 1, wherein the taxol or the derivative thereof is administered in an amount of from about 0.005 to 5 μg.
Claim 7
Dependent Claim
25 words
A method as defined by claim 1, wherein the taxol or the derivative thereof is administered in an amount of from 0.1 to 5 μg.
Claim 8
Dependent Claim
20 words
A method as defined by claim 1, wherein the taxol or the derivative thereof is administered in a microcrystalline form.
Claim 9
Dependent Claim
21 words
A method as defined by claim 1, wherein the taxol or the derivative thereof is administered in a slow release composition.
Claim 10
Dependent Claim
22 words
A method as defined by claim 1, wherein the taxol or the derivative thereof is administered in an ophthalmologically acceptable viscoelastic medium.
Claim 11
Dependent Claim
18 words
A method as defined by claim 9, wherein the viscoelastic medium comprises an aqueous solution of hyaluronic acid.
Claim 12
Dependent Claim
22 words
A method as defined by claim 9, wherein the visoelastic medium is administered in an amount of from 0.1 to 0.3 ml.
Claim 13
Dependent Claim
43 words
A method as defined by claim 1, wherein the taxol or a pharmaceutically active and opthalmologically acceptable derivative thereof is administered in microcrystalline form in an amount of about 0.005 to 5 μg in approximately 0.1 ml of an aqueous hyaluronic acid solution.
References Cited (Backward Citations)
US5252319A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-11-19 | 2000-05-20 | 2000-11-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-11-19 | 2004-05-20 | 2004-11-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-11-19 | 2008-05-20 | 2008-11-19 | $7700.00 | Window Closed / Lapsed |